On December 11, 2025, Immunovant, Inc. (IMVT) announced the pricing of an underwritten public offering of its common stock. The 8-K filing disclosed anticipated gross proceeds of approximately $550 million, with the offering expected to close on December 12, 2025, according to the company's SEC filing.

The company stated that existing cash and offering proceeds will fund operations through the potential commercial launch of IMVT-1402 in Graves Disease. Immunovant is developing IMVT-1402, an anti-FcRn therapy, across six autoimmune indications including Graves Disease, Difficult-to-Treat Rheumatoid Arthritis (D2T RA), Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy, Sjögren's Disease, and Cutaneous Lupus Erythematosus.

Immunovant initiated a potentially registrational trial for IMVT-1402 in anti-citrullinated protein autoantibody (ACPA) positive D2T RA in December 2024. The company expects to report top-line results from this trial in 2026, with Graves Disease trial results anticipated in 2027, according to the filing.

"We are prioritizing the rapid development of IMVT-1402 across a broad set of programs as a potential first- and best-in-class anti-FcRn therapy." — Immunovant, Inc. SEC 8-K Filing

Regarding its partnered asset, Immunovant has commenced discussions with HanAll regarding the potential return of certain rights for batoclimab. The company expects the first of two Phase 3 Thyroid Eye Disease (TED) studies for batoclimab to read out before the end of 2025, with concurrent top-line results from both studies anticipated in the first half of 2026.

Chief Financial Officer Tiago Girão signed the report on behalf of the company. The filing included numerous risk factors related to clinical trial execution, regulatory uncertainties, and potential disputes with partner HanAll over batoclimab rights.